ADMA Biologics, Inc. Faces Class Action Suit After Investor Losses Amid Allegations
ADMA Biologics, Inc. Faces Class Action Suit After Investor Losses Amid Allegations
In a significant development for investors of ADMA Biologics, Inc. (NASDAQ: ADMA), the law firm Robbins Geller Rudman & Dowd LLP has announced the opportunity for individuals who have incurred substantial financial losses from their investment in the biopharmaceutical company to lead a class action lawsuit. This comes in response to troubling allegations concerning the company's financial practices and the behavior of its top executives during a specific period.
Key Details of the Class Action Lawsuit
The class action lawsuit, identified as Mazzarino v. ADMA Biologics, Inc., No. 26-cv-06918 (D.N.J.), pertains to purchases or acquisitions of ADMA Biologics’ publicly traded securities from August 9, 2024, to March 25, 2026. Investors wishing to take part need to act quickly, as the deadline to seek appointment as lead plaintiff is August 10, 2026.
According to the allegations, ADMA Biologics, a company focused on developing and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases, has reportedly engaged in misleading practices. During the designated class period, ADMA Biologics supposedly made false statements and failed to disclose essential information that directly affected the company’s stock performance.
Allegations Against ADMA Biologics
The core of the allegations involves three essential points:
1. Undisclosed Related Party Transactions: ADMA Biologics is accused of conducting undisclosed transactions with related parties, raising significant concerns about transparency and ethical business practices.
2. Channel Stuffing Practices: The lawsuit claims that the company employed channel stuffing, artificially inflating sales figures to create an impression of improved revenue performance.
3. Insufficient Internal Controls: It has been further asserted that ADMA Biologics lacked the necessary internal controls to ensure accurate financial reporting, which is crucial for investor trust and market integrity.
The turning point came on March 24, 2026, when Culper Research published a report criticizing ADMA’s revenue reporting, likening it to a ‘fiction inflated by channel stuffing’ and suggesting that without extending payment terms, the company would have reported a revenue decline instead of growth.
Investor Reaction and Stock Performance Impact
Following the release of this report, ADMA Biologics’ stock plummeted over 16% in value. In response, the company attempted to counteract these claims in a press release on March 25, asserting that the allegations were based on unreliable sources. However, market confidence did not fully return as Cantor Fitzgerald downgraded the company's stock rating, further aggravating the decline with an additional 13% drop in stock price reported on March 26.
The Lead Plaintiff Process
Under the Private Securities Litigation Reform Act of 1995, investors who purchased ADMA Biologics securities during the specified timeframe may seek to be appointed as lead plaintiffs. The individual selected will serve as a representative for the entire class, directing the lawsuit and selecting legal counsel of their choice. Importantly, being a lead plaintiff may allow for greater involvement but does not impact the ability to participate in any potential financial recovery.
About Robbins Geller Rudman & Dowd LLP
Robbins Geller is renowned for its advocacy in securities fraud and shareholder rights litigation, ranking at the top for recovering substantial amounts for investors. The firm has a proven track record, recovering over $8.4 billion for investors in recent years, boasting a strong team of approximately 200 lawyers across ten offices. The firm is widely recognized within the legal community for achieving some of the largest class action recoveries in U.S. history.
Investors interested in pursuing this class action are encouraged to provide their information to initiate the process or get in touch with attorneys at Robbins Geller for further assistance on navigating this complex situation. As details continue to unfold, the implications for ADMA Biologics and its investors remain to be seen.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.